Monopar Therapeutics Annual Operating Income (Loss) in USD from 2016 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Monopar Therapeutics quarterly/annual Operating Income (Loss) history and growth rate from 2016 to 2024.
  • Monopar Therapeutics Operating Income (Loss) for the quarter ending December 31, 2024 was -$11.1M, a 479% decline year-over-year.
  • Monopar Therapeutics Operating Income (Loss) for the twelve months ending December 31, 2024 was -$16.2M, a 83% decline year-over-year.
  • Monopar Therapeutics annual Operating Income (Loss) for 2024 was -$16.2M, a 83% decline from 2023.
  • Monopar Therapeutics annual Operating Income (Loss) for 2023 was -$8.83M, a 16.2% increase from 2022.
  • Monopar Therapeutics annual Operating Income (Loss) for 2022 was -$10.5M, a 15.4% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$16.2M -$7.33M -83% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-31
2023 -$8.83M +$1.71M +16.2% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-31
2022 -$10.5M -$1.41M -15.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$9.13M -$2.62M -40.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 -$6.51M -$2.19M -50.5% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-24
2019 -$4.32M -$993K -29.8% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
2018 -$3.33M +$13.3M +79.9% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-27
2017 -$16.6M -$15.4M -1292% Jan 1, 2017 Dec 31, 2017 10-K 2019-02-26
2016 -$1.19M Jan 1, 2016 Dec 31, 2016 10-K 2018-03-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.